Director of the Neuroscience Institute (Ref: 6972) - Harvey Nash

CANDIDATE INFORMATION PACK
Director of the
Neuroscience Institute
(Reference: 6972)
HAMAD MEDICAL CORPORATION – AUGUST/SEPTEMBER 2012
HAMAD MEDICAL CORPORATION | 1

Appointment of
Director of the Neuroscience Institute
Contents
Welcome letter from Professor Edward Hillhouse 3
An overview of Hamad Medical Corporation 5
Academic Affiliations and Clinical Partnerships 8
Details about the role (including job description) 10
Terms and conditions 14
The advert 15
The application and selection process 16
HAMAD MEDICAL CORPORATION | 2

Welcome letter
Dear Colleague
Director of the Neuroscience Institute
I am delighted that you have expressed an interest in the Director of the
Neuroscience Institute at Hamad Medical Corporation (HMC). Qatar has one of
the highest GDPs in the world and one of its strongest economies. It is a rapidly
expanding community, with the population growing from 600,000 to almost 2
million from 2000 to 2012, with a very large growth in the expatriate workforce.
It is against this backdrop that we are transforming how we deliver healthcare
across Qatar.
Today the Emir, His Highness Sheikh Hamad Bin Khalifa Al-Thani’s vision is
to provide high quality healthcare services to all, which meet the best global
standards of quality and outcomes. Consequently, this is an especially exciting
time for healthcare provision in the State of Qatar.
HMC presents a unique opportunity in global healthcare. One where there
is a complete focus on the quality of our patient care underpinned by the
development of the world’s newest Academic Health System (AHS), which
will lead the transformation of health services through an integrated approach
to clinical practice, education and research.
Equally, in order to develop an integrated world-class healthcare system HMC
is investing heavily in high class research and education, and has some highly
prestigious partners including Weill-Cornell Medical School. Further investment
is being made in preventive, primary, secondary and tertiary healthcare provision.
Qatar’s Vision for 2030 puts healthcare at the core of its future strategy.
In order to deliver on our promises, we need the best clinical leaders and
academics. Some of the world’s leading clinicians are already working with HMC.
For example, our International Advisory Board includes internationally renowned
clinicians, such as:
• The Right Hon Professor the Lord Darzi, Chair of Imperial College Institute
for Global Health Innovation and AHSC, Imperial College, London
• Dr Victor Dzau, President and CEO, Duke University Health System
• Professor Martin Paul, President and Chairman of the Executive Board,
Maastricht University
• Dr Steve Wartman, President and CEO, Association of Academic Health Centers
• Dr John Wong, Deputy Chief Executive, the National University Health System,
Singapore
HAMAD MEDICAL CORPORATION | 3

Welcome letter
However, as we develop, we need more talented clinicians to join us. We have
commissioned a specialist executive healthcare search firm to support us in this
work. We would be delighted for you to contact them to explore your candidacy
further. The dedicated team for HMC is:
Frank McKenna
Simon Green
Chris Davies
Thomas Patterson
Managing Director – Healthcare
Director of Healthcare
Director of Healthcare
Head of Healthcare Research
Please contact them on +44 (0)20 7333 1516.
Alternatively, email pippa.hogg@harveynash.com
or kat.kamsika@harveynash.com to arrange a mutually convenient time
to speak with one of the team.
The Harvey Nash team would be more than happy to have a confidential
discussion about any of these posts with you in detail if this would be helpful.
We are providing further information about this role on our dedicated microsite
www.harveynash.com/HMC, and this will be continually updated over the coming
weeks. If you feel the opportunities at HMC appeal to you, then we look forward
to receiving your application.
Yours faithfully
Professor Edward Hillhouse
Chief Policy Advisor on Academic Health Systems
and Chief of Medical, Academic and Research Affairs
Hamad Medical Corporation
Qatar
HAMAD MEDICAL CORPORATION | 4

An overview of
Hamad Medical Corporation
Hamad Medical Corporation (HMC) is the premier not-for-profit
healthcare provider in Qatar. Established by Emiri decree in
1979, the Corporation has developed highly specialised medical
facilities capable of providing state-of-the-art diagnosis and
treatment of diseases that previously could only be managed
in overseas medical centers. Today the Emir, His Highness
Sheikh Hamad Bin Khalifa Al-Thani’s vision is to provide high
quality healthcare services to all, which meet the best global
standards of quality and outcomes. Consequently this is an
especially exciting time for healthcare provision in the State
of Qatar with a recent major restructuring of the system and
a concomitant large scale expansion of healthcare services.
In order to develop an integrated world class healthcare system
HMC is investing in high class research and education in
addition to preventive, primary, secondary and tertiary
healthcare provision.
The backdrop to these transformational changes is a rapidly
expanding population in Qatar. Key health conditions in Qatar,
aside from trauma injuries, are cardiovascular disease and
hypertension, diabetes, respiratory conditions and asthma,
obesity and other chronic conditions with related and costly
long term care implications.
The health system in Qatar is almost totally government funded
but there are recent developments in private sector provision.
There are other initiatives in place covering health insurance
models and also the introduction of an element of self pay for
non Qatari nationals.
Current Service Provision
Hamad Medical Corporation is an integrated and growing
healthcare delivery system that currently provides 90-95%
of acute and sub-acute care services in Qatar. It is the largest
employer in Qatar, with over 20,000 staff (rising by several
thousand by the end of 2013), and is one the largest healthcare
providers in the Middle East.
At the current time, its portfolio includes seven hospitals, a
comprehensive ambulance service and Home Healthcare Services.
All hospitals are JCI accredited, having been awarded initial
accreditation in 2006 and having received re-accreditation
in subsequent years to date.
The current hospitals are:
• Hamad General Hospital
• Rumailah Hospital
• Women’s Hospital
• Al Khor Hospital
• The National Center for Cancer Care and Research (NCCCR)
• The Cuban Hospital in Dukhan
• The Heart Hospital
• Al Wakra Hospital
Hamad Medical Corporation aspires to realise its ambitious
vision of being an internationally recognised centre of
excellence in the provision of healthcare; in keeping with the
State of Qatar’s pledge of “Health for All”. HMC prides itself on
providing quality and cost efficient healthcare for all patients,
regardless of their nationality.
The Corporation’s Vision is based on three pillars:
• Health
• Education
• Research
HAMAD MEDICAL CORPORATION | 5

An overview of
Hamad Medical Corporation
Hospital Services Beds Specialty Occupancy
Hamad General Hospital
• Trauma
• Emergency Medicine
• Pediatrics
• Critical Care
• Specialised Surgery
• Specialised Medicine
• Laboratory Medicine
• Radiology
443
102
58
Adult
Pediatrics
Critical Care
96%
96%
84%
Rumailah Hospital
• Adult Rehabilitation
• Children’s Rehabilitation
• Burns & Plastics
• Dental
• General Surgery
• General Medicine
• Psychiatry
• Residential Care
427
30
60
28
58
Adult
Pediatrics
Mental
Health
Residential
Long Term
87%
84%
90%
Women’s Hospital
• Obstetrics
• Gynaecology
• Neonatal
• Emergency Care
• Newborn Screening
248
71
Adult
NICU
68%
80%
NCCCR
• Medical Oncology
• Radiotherapy
• Chemotherapy
• Pain Management
• Specialist Laboratory
76 Adult 88%
Al Khor
• General Medicine
• General Surgery
• Emergency Medicine
• Pediatrics
• Obstetrics
115
22
12
Adult
Pediatrics
Critical Care
79%
53%
69%
HAMAD MEDICAL CORPORATION | 6

An overview of
Hamad Medical Corporation
Hospital I/P Surgery Day Cases ED Attendances Deliveries Out patient Visits
Hamad General 14,223 4,572 501,537 382,084
Rumailah 3,194 3,741 210,255
Women’s
Hospital
5,149 242 47,741 15,532 126,710
Al Khor 2,755 1,397 122,843 443 59,499
NCCCR 5,350 14,211
Total 25,318 15,302 672,121 15,975 792,759
Emergency Medical Services (EMS) attended to more than
85,000 incidents last year with the Life Flight Air Ambulance
service responding to 600 calls requiring critical care support.
Home Healthcare, which formally launched in 2009 and
received JCI accreditation in 2010, undertook over 9,000
home visits.
HMC no longer administers the 23 Primary Healthcare Centers
in the State. PHC has been established as a Department of
the Supreme Council for Health but HMC provides support on
Clinical Education, IT, Facilities Development and Materials
Management to a sector that is expected to see rapid
development over the next decade.
New Facilities
HMC is embarking on one of the biggest and most ambitious
master facility plans ever seen in international healthcare,
with a range of facilities opening this year or being planned
for future years.
Qatar’s Public Works Authority (ASHGHAL) and South Korea’s
Hyundai Engineering & Construction Company have signed
a QR1.9 billion deal for furnishing and equipping three
state-of-the-art hospitals and a research center.
The planning of the hospitals is taking into consideration
the highest medical standards and the latest international
technologies to make them the best pioneering healthcare
facilities in the region. Work began in early 2011 and is
scheduled for completion in 2013.
As the master plan is implemented, by 2013, a Women’s
Hospital with 190 private rooms, a Minimally Invasive Day
Surgery Center, a Rehabilitation Hospital and a Translational
Research building will be opened to introduce new services
and significantly increase the capacity of our system to meet
our population’s growing demand.
HAMAD MEDICAL CORPORATION | 7

Academic Affiliations
& Clinical Partnerships
Hamad Medical Corporation’s vision is to achieve international
recognition as a world-class quality healthcare provider,
supported by partnerships with international health providers
and academic institutions to foster the three pillars of health,
education and research.
• Medical Education & Training
Weill-Cornell Medical School – Qatar
• Nurse Education & Training
University of Calgary – Qatar
• Allied Health Training
College of the North Atlantic – Qatar
• Post Graduate Nurse Training
Deakin University – Australia
• Paediatrics
Hospital for Sick Children – Toronto
• Radiotherapy
Heidelberg University
• Newborn screening
Heidelberg University
• Mental Health
Asia Mental Health
• Quality and Governance
Partners – Boston
• Cardiovascular services
The Cleveland Clinic
HAMAD MEDICAL CORPORATION | 8

Academic Affiliations
& Clinical Partnerships
The Academic Health System
The healthcare system in Qatar is state funded and available
to all at little or no cost via a network of hospitals and
healthcare centers delivering healthcare. Although most of
the hospital system is integrated through Hamad Medical
Corporation, primary care and the various academic institutions
also need to be aligned with the hospital sector to provide
optimal pathways of care and programmes of research.
The Academic Health System initiative is designed to achieve
this, aligning the various strands with a single mission and
vision. These health systems are a potential solution to
integration problems because of their unique combination
of teaching, research, and patient care. Their strength results
from the seamless integration of these central activities to
improve health and well being, search for innovative
healthcare solutions, and ensure a modern, flexible, and
sustainable workforce. The Academic Health System
partnership will enable multidisciplinary teams to address key
research questions and ensure rapid translation into clinical
practice. To be leading organisations of the future, Academic
Health Systems should be focused directly on their communities
and regions. This focus involves development of a social
conscience and provision of tangible economic and personal
health benefits to the community. These social determinants of
health include an individual’s social circumstance, environment,
and behavioural patterns.
With this approach HMC aims to identify new ways of
working, which will make the Qatari population less dependent
on hospitals, by harnessing modern technology and a flexible
and skilled workforce to help shift the emphasis from
secondary care to primary care and prevention. The Academic
Health System initiative website has information about the
partners, governance arrangements, strategy, and its
distinguished international advisory board. Each institution
will remain legally independent, but united with a shared vision
and an overarching strategic plan.
We have developed a translational research institute at Hamad
Medical Corporation to complement the other biomedical
research facilities in Qatar, including state-of-the-art core
research facilities at Weill Cornell Medical College in Qatar.
The Institute will host the Qatar Biobank, funded by the Qatar
Foundation, which will include a prospective epidemiological
study of the Qatari population (in collaboration with Imperial
College, London, UK) and a disease-specific tissue repository.
The indigenous Qatari population provides a potentially
important study group because it is stable and derived from
three main genetic sources – the Arabian Peninsula, Iran,
and Africa.
For the AHS website, see http://www.hmc.org.qa/ahs
Qatar has a unique opportunity to embrace this concept and
develop a distinctive Academic Health System, which will
allow the diverse academic institutions and healthcare
providers to work in harmony for the public good, and seek
sustainable and affordable healthcare solutions. This
development includes embedding of a public health system
and exploration of innovative health system designs and
new models of healthcare delivery.
HAMAD MEDICAL CORPORATION | 9

Details about the role
Background of the Neuroscience Institute
In collaboration with Weill Cornell Medical College in Qatar,
Hamad Medical Corporation (HMC) has begun development
of specialised institutes, which will improve health outcomes
for Qatar’s population by focusing on conditions that are
particularly relevant to the local population. Using an
integrated approach to research, training and clinical activities,
the institutes will deliver and unite inter-professional clinical
service programs across various specialties. At present,
institutes are planned across cardiovascular disease, metabolic
disease, cancer and neurosciences.
Neurological and Neuropsychiatric disorders represent a major
healthcare problem for Qatar. Although no prevalence study
has taken place in Qatar, HMC clinical data identifies the main
disorders as epilepsy, brain injury (trauma, stroke, demyelination,
tumours and degenerative disease), headaches, spinal cord
injury, neuromuscular disorders, peripheral nerve injury
(particularly diabetic neuropathy), depression, schizophrenia
and movement disorders. The incidence of stroke, in particular,
is likely to increase over the next decade as it is inextricably
linked with type II diabetes and hypertension.
The Neuroscience Institute will provide a framework to apply
the latest developments in neuroscience to the study and
management of nervous system disorders. It will bring together
an inter-professional network of clinicians and neuroscientists
who are actively collaborating on a range of research
initiatives. The ‘virtual institute’ structure will draw in members
from across the Academic Health System (AHS) to work
together to improve the care of patients with neurological
disorders by embedding research and education into everyday
clinical practice.
Functionalities
In the initial phase, the Neuroscience Institute will establish
clinical, educational and research programs relevant to the
disease patterns and trends prevalent in the population of
Qatar. This will require close cooperation with the AHS
partners to ensure that all the components of the tripartite
mission (clinical care, education and research) are delivered
within the context of multidisciplinary teams and programs.
The clinical programs will be based on international best
practice and academic partners will work closely with clinical
teams to ensure that the educational programs can train and
develop professionals with the appropriate skill mix. The
emphasis will be on flexible teams that can adapt to new
methods of working as they evolve to ensure that Qatar’s
population will receive the highest quality and safest care
available. While the Institute will need to be comprehensive
and serve all neurological patients, initial focus will be placed
upon the development of centers of excellence that can
compete on an international level. These areas are likely to be:
• Brain injury (including stroke)
• Epilepsy
• Depression, schizophrenia and mood disorders
• Neural stem cell research
HAMAD MEDICAL CORPORATION | 10

Details about the role
These programs will need the support and further development
of a number of cross cutting technologies such as functional
genomics, clinical trials, imaging and stem cell biology. Other
possible clinical programs include:
• Neurogenetics
• Pediatric neurology
• Geriatric neurology
• Headache and pain
• Neurodegenerative disorders
• ICU neurology and neurosurgery
• Movement disorders
• Spine disorders (including tumours and spinal cord injury)
• Pain management
In addition, the Institute will develop research programs that
break new ground in clinical pathways and the rehabilitation
of neurological patients. The aim will be to reduce the burden
of disability within the population and there will need to
be a strong collaboration between the Institute and the
Rehabilitation Hospital. These research programs will be
undertaken in collaboration with the AHS partners and will
be facilitated through HMC’s forthcoming Translational
Research Institute (TRI).
Long-term, sustainable partnerships with leading international
neuroscience centers will be a key element in the success
of the Institute. The center will facilitate international
neuroscience research collaborations in the region including
the potential for pharmaceutical/biotechnology companies
to initiate research programs and transfer technology.
Facilities
At the outset, the Neurosciences Institute will be virtual,
with a focus on integrating clinical, education and research
activities across the spectrum of neurological specialties.
The Institute will incorporate and build upon the existing
facilities, personnel and infrastructure available within each
of the clinical specialty areas. At present, within the Institute’s
developmental phase, plans are being developed to audit and
identify additional human and physical capital which will be
required to develop a framework for world-class clinical care,
education and research within the Institute. The physical
structure may ultimately include inpatient wards, outpatient
clinics, multidisciplinary disease oriented programs,
a specialised neuro-intensive care unit, a clinical
neurophysiology diagnostic laboratory, an advanced neuroimaging
facility, a sleep-epilepsy monitoring unit, neurosurgical
operating rooms, basic neuroscience laboratories, and any
other facilities that may be developed in the future.
At a later stage, the Institute will be linked to HMC’s TRI.
Scheduled for completion in 2014, the TRI will provide
state-of-the-art core research facilities to facilitate internationally
competitive outcomes in translational (bench to bedside) and
clinical research. With a focus on the fields of cancer, trauma,
infectious diseases, neuroscience, diabetes, obesity,
cardiovascular disease, and women’s and children’s health,
the TRI will provide researchers with ready access to facilities
which would otherwise be unavailable, leading to the
translation of basic biomedical discoveries into new diagnostic
biomarkers and therapies.
The facility will consolidate research groups across HMC and
the AHS partners, and encourage collaboration and innovation
through a number of crosscutting themes such as bioinformatics,
ethics, molecular imaging, functional genomics, proteomics and
metabolomics, clinical imaging, clinical trials and biostatistics.
HAMAD MEDICAL CORPORATION | 11

Details about the role
Our Ambitions and Strategy
The strategic aims of the Neuroscience Institute will be aligned
with those of the AHS partners and the national research
priorities. In brief, the Neuroscience Institute will:
• Pool all brain disease specialties undertaken by HMC and its
academic partners within one organisational structure in the
form of an institute
• Foster the development of functional multi-disciplinary
clinical service programs in the different neuroscience
specialties
• Improve neurological and mental health outcomes for all
patients through a multidisciplinary approach in research,
training and clinical activities through the collaboration
between the different units of the Institute
• Ensure the provision of highly relevant undergraduate,
postgraduate and continuing professional development
programs in neuroscience
• Establish the research and intellectual infrastructure, in
collaboration with the Translational Research Institute, our
academic partners, Qatar Foundation, and Supreme Council
of Health, to support the neuroscience community
• Establish a comprehensive neuroscience seminar program
and an annual neuroscience retreat
• Have a very strong public health component to promote
patient education and awareness, disseminate latest findings
from relevant research, and become a key resource for Qatar
and the entire region
The Role
Director of the Neuroscience Institute
Summary of the role
The Director of the Neuroscience Institute will provide
leadership and direction across all areas of the Institute.
The Director will report to the Chief of Medical, Academic
and Research Affairs and will have responsibility for preparing
regular reports on progress to the Academic Health System
Joint Steering Committee and to an Executive Committee
consisting of representatives from the various AHS partners.
The Director will also work in consultation with, and chair,
a Scientific Advisory Committee (SAC) appointed by the
Executive Committee.
The principal accountabilities of the role:
Clinical and academic leadership:
• Provide clinical, professional and academic leadership
in neuroscience
• Lead and support multidisciplinary clinical engagement
in service improvement
• Motivate and inspire all staff engaged in clinical or academic
neuroscience
• Develop a vision and strategic plan for the Neuroscience
Institute that aligns with those for the Academic
Health System
• Nurture a culture of critical enquiry and develop research
capacity in neuroscience
• Review the skill-mix of the healthcare workforce and
develop a sustainable plan for recruitment and development
including specific plans for development of Qatari Nationals
• Ensure that the residency programs satisfy ACGME
requirements for accreditation
• Ensure the provision of high quality educational programs
• Provide a clinical service in a sub-specialty of neuroscience
as appropriate
HAMAD MEDICAL CORPORATION | 12

Details about the role
Clinical quality and patient safety:
• Lead the quality and patient safety agenda introducing
clinical standards capable of international accreditation
• Ensure departmental adherence to JCI standards
• Develop links between the quality and safety agenda and
those areas that impact on quality and safety, such as
research and teaching
Administration and engagement
• Develop strong links with our academic and clinical
partners such as Weill-Cornell Medical College, Qatar
University and SIDRA
• Take a national leadership role in issues relating
to neuroscience
• Take a lead role in planning for the future through
further service and specialty reconfiguration
• Represent the Academic Health System on the international
stage and develop strong international partnerships
The Candidate
The ideal candidate will be a Clinical Scientist with a track
record in senior medical or scientific leadership gained either
in an Academic Medical Center or in a complex healthcare
setting such as an international teaching hospital. He/she
will have gravitas and presence as well as the ability to act
as a role model and support staff and student development.
An academic background and significant achievement in
research is essential.
Specifically he/she will demonstrate the following key skills
and experience:
• Board certification or equivalent specialist qualification
in a sub-specialty of neuroscience
• Strong clinical and/or academic leadership skills and the
ability to contribute to strategy and policy development
at Institutional level
• Strong networking and team building skills
• The ability to contribute to complex policy development
• Strong analytical and communication skills
• An ability to work as part of an inter-professional team
• A strong academic background
• Clear evidence of working in a multicultural environment
HAMAD MEDICAL CORPORATION | 13

Terms and Conditions
The chosen candidate will be offered a generous package,
which in most circumstances would be tax-free. Further details
will be discussed on an individual basis with candidates as the
selection process moves forward.
However, as a minimum the package includes:
• Business class return flights for the jobholder and his/her
immediate family each year, as well as business class flights
at the start and end of the contract
• Conference and study leave, including flights and
living allowances
• Highly attractive tax-free salary
• High quality free accommodation
• Generous vacation/holiday leave, 50 days per annum
plus religious holidays (approximately 10 days)
• Contribution towards school fees
HAMAD MEDICAL CORPORATION | 14

The advert
Join the healthcare
transformation
of a nation
Hamad Medical Corporation (HMC) is the premier provider of secondary and tertiary care in Qatar, and one of the
leading healthcare providers in the Middle East. As the driving force behind the Academic Health System being rolled
out nationwide in collaboration with Weill-Cornell Medical College in Qatar, HMC is committed to providing quality
patient care based on international best practice.
To take forward our transformation, we are looking for three highly experienced clinical leaders.
The Director, Neuroscience Institute will provide leadership
and direction across development of the institute, oversight
of research programs that break new ground in clinical
pathways and the rehabilitation of neurological patients.
The Director, National Center for Cancer Care & Research
will develop a vision and strategic plan for the organisation
that aligns with those for the Academic Health System.
With demonstrable leadership experience in a comparable
complex organisation, the successful candidate will take a
lead role in planning for the future through further service
and speciality reconfiguration and further develop links with
our academic and clinical partners such as Weill Cornell
Medical College, Qatar University and SIDRA.
The Chair of Dermatology will help promote the rapid
application of basic science and clinical research discoveries
to the development of new therapies in dermatology.
Fostering the growth of world-class dermatology research
at HMC, the Professor will be an outstanding individual
with a distinguished research record in dermatology.
The opportunity to help shape the level of secondary and
tertiary healthcare in such a rapidly developing landscape is
an exciting and rewarding prospect for any experienced
professional who is keen to share their expertise with others.
For further information please visit
www.harveynash.com/HMC
For an informal, confidential discussion please call
our retained advisors at Harvey Nash:
Frank McKenna
Managing Director of Healthcare
Simon Green
Director of Healthcare
on +44 (0)20 7333 1516
HAMAD MEDICAL CORPORATION | 15

Application and Selection Process
In the first instance, please call our retained recruitment
consultants, Harvey Nash, for an informal, confidential
discussion:
Frank McKenna – frank.mckenna@harveynash.com
Managing Director – Healthcare
Simon Green – simon.green@harveynash.com
Director of Healthcare
Chris Davies – chris.davies@harveynash.com
Director of Healthcare
Thomas Patterson – thomas.patterson@harveynash.com
Head of Healthcare Research
On +44 (0)20 7333 1516
How to apply
Next steps
Selected candidates may be invited for a first round interview.
This could be by video conference.
Shortlisted candidates will subsequently be invited to visit
HMC in Doha and to meet with key members of staff and to
discuss the role in more depth, leading to a formal interview
process thereafter. It is expected that these visits will take
place in late September or early October 2012.
Please confirm your availability for visiting Doha, including
dates you are unable to travel. All reasonable travel costs
will be covered by HMC.
Closing date for applications Wednesday 12th September 2012.
Candidates will be notified of further key dates as they
progress through the recruitment process.
Your application should comprise a full CV detailing your
experience and relevant achievements pertaining to this role,
particularly addressing the requirements of the job description,
and must include details of current reward arrangements.
This role is only available on a full time basis, and the
successful candidate will be required to relocate to Doha.
The application should be sent to health@harveynash.com
quoting the specific job reference number for the position
(Reference 6972).
Please note we are unable to accept an application without
a cover letter or clear reference to the opportunity.
HAMAD MEDICAL CORPORATION | 16